Clovis gets global license to Pfizer's PARP inhibitor PF01367338
Pfizer Inc. has licensed Clovis Oncology Inc. (developing therapeutics and diagnostics for cancer) worldwide rights to develop and commercialize oral and IV formulations of its Phase I/II potent poly (ADP-ribose) polymerase (PARP) inhibitor PF01367338 for solid tumors.
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.